QuidelOrtho (NASDAQ:QDEL) Issues FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.070-2.570 for the period, compared to the consensus estimate of 2.450. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on QDEL. Jefferies Financial Group started coverage on QuidelOrtho in a research note on Tuesday, December 10th. They set a “hold” rating and a $43.00 target price for the company. Citigroup upgraded QuidelOrtho from a “neutral” rating to a “buy” rating and increased their price objective for the company from $44.00 to $50.00 in a research report on Wednesday, December 11th. StockNews.com upgraded QuidelOrtho from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Finally, William Blair reaffirmed a “market perform” rating on shares of QuidelOrtho in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $53.43.

QuidelOrtho Stock Performance

QDEL stock traded down $1.53 on Wednesday, reaching $39.94. 1,309,639 shares of the company were exchanged, compared to its average volume of 889,851. The stock’s fifty day moving average price is $43.28 and its 200 day moving average price is $42.36. The firm has a market capitalization of $2.69 billion, a PE ratio of -1.43 and a beta of 0.08. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.38 and a quick ratio of 0.81. QuidelOrtho has a 12 month low of $29.74 and a 12 month high of $68.85.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 66.25% and a positive return on equity of 4.24%. On average, research analysts anticipate that QuidelOrtho will post 1.73 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $35.31, for a total value of $291,667,061.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Brian J. Blaser acquired 6,033 shares of QuidelOrtho stock in a transaction on Wednesday, December 11th. The shares were purchased at an average cost of $41.42 per share, for a total transaction of $249,886.86. Following the acquisition, the chief executive officer now owns 6,033 shares in the company, valued at approximately $249,886.86. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. 1.00% of the stock is currently owned by corporate insiders.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.